#India #healthcare #Mumbai #pharmaceuticals #Piramal Pharma

Piramal Pharma's 2026 Annual Report: A Testament to Growth and Sustainability

Piramal Pharma Limited (PPL), a prominent player in the global pharmaceutical and healthcare sector, has unveiled its Annual Report for the fiscal year 2026. This report not only highlights the remarkable financial achievements of the company but also reflects its unwavering commitment to innovation and sustainability.

Global Reach and Financial Performance

In FY2026, Piramal Pharma reported a significant operation revenue of 8,869 Crore Rupees, fueled by a robust and diversified business model. The company has established a solid global platform with 17 development and manufacturing sites, serving over 100 countries worldwide. Remarkably, approximately 66% of its revenue was generated from regulated markets, showcasing its strong international footprint and adaptability to global standards.

Nandini Piramal, Chairperson of Piramal Pharma, emphasized the challenges faced during the fiscal year due to external disruptions and business-specific factors. She noted that despite these hurdles, the company successfully concluded the year with improved execution across all business sectors, enhancing visibility for future growth.

Key Highlights from the Report

The report sheds light on several critical areas of development within the company:
1. Piramal Pharma Solutions (CDMO): This segment accounted for 55% of the company’s revenue, solidifying its status as a leader in integrated Contract Development and Manufacturing Organization (CDMO) services. The unit supported over 500 clients in the pharmaceutical and biotechnology sectors and made strategic investments, including a noteworthy $90 million in expanding capacity for sterile injectables.

2. Piramal Critical Care (CHG): This arm of the business further bolstered its leadership in the US inhalation anesthetics market, maintaining its top position in Sevoflurane. Moreover, the integration of Kenalog further enhanced its service offerings, ensuring support to over 6,000 hospitals and clinics globally.

3. Piramal Consumer Healthcare: Achieving revenue of 1,274 Crore Rupees, this division expanded its portfolio by launching 31 new products in FY2026, with 'Power Brands' growth of 24%, contributing significantly to overall sales.

4. Quality and Compliance: Quality control remains imperative for Piramal Pharma, as evidenced by its successful completion of 38 regulatory inspections, including three by the US FDA, all without any OAI comments. This underlines the strength of its quality systems and commitment to regulatory compliance.

5. Sustainability Efforts: As part of its sustainability agenda, the company achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions, aligning with its science-based decarbonization targets approved earlier this year.

6. Employee Well-Being: Piramal Pharma prides itself on its 'People-First' culture, with a workforce of over 7,285 employees. Impressively, the company reported no fatal workplace accidents for the fifth consecutive year, reinforcing its commitment to safety and health.

Looking Ahead

The report not only underscores the accomplishments of Piramal Pharma in FY2026 but also sets a positive tone for the future. The company is well-positioned to leverage its robust innovation strategy along with strong operational capabilities to enhance patient outcomes and meet the demands of regulated markets globally.

For further insights, detailed financial data, and strategic goals, the complete report is accessible online. Piramal Pharma remains committed to advancing healthcare through innovation while maintaining its dedication to sustainability and corporate responsibility.